Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value

^aFrom the Departments of Radiology (R.-E.Y., S.H.C., T.J.Y., J.-H.K, C.H.S)
^bPathology (S.-H.P.)
^cDepartments of Internal Medicine (S.-H.L., T.M.K.)
^dRadiation Oncology (C.H.S., I.H.K.), Cancer Research Institute
^eDepartment of Neurosurgery (C.-K.P.), Biomedical Research Institute; Seoul National University College of Medicine, Seoul, Korea
^fCenter for Nanoparticle Research (R.-E.Y., S.H.C.)
^gInstitute for Basic Science and School of Chemical and Biological Engineering (R.-E.Y., S.H.C.), Seoul National University, Seoul, Korea.

Please address correspondence to Seung Hong Choi, MD, PhD, Department of Radiology, Seoul National University College of Medicine, 28, Yongon-dong, Chongno-gu, 110–744, Seoul, Korea; Center for Nanoparticle Research, Institute for Basic Science and School of Chemical and Biological Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, 151–742, Seoul, Korea; e-mail: verocay{at}snuh.org